ArticleGastro hep advances2025
Complete Response of Hepatocellular Carcinoma With Inferior Vena Cava Tumor Thrombus and Right Atrium Involvement to Combined Radiotherapy and Immunotherapy: A Case Report.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 66-year-old male with advanced hepatocellular carcinoma, including the portal vein and inferior vena cava tumor thrombi extending to right atrium, received Atezolizumab/Bevacizumab and radiotherapy. In the first 2 weeks, he exhibited fever, elevated C-reactive protein and lactate dehydrogenase levels, and intratumoral bleeding, indicating an antitumor immune response. He achieved a complete response by week 6, maintained until week 89, despite grade 3 pneumonitis and grade 2 proteinuria. This case demonstrates that combining radiotherapy and immunotherapy can be an effective and tolerable treatment for advanced hepatocellular carcinoma with macrovascular invasion, though further studies are needed to confirm the safety and efficacy of this strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.